The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke: A Secondary Analysis From a Double-Blind, Randomized Trial

Hyun Mi Oh; Geun Young Park; Young Min Choi; Hyung Jung Koo; Yongjun Jang; Sun Im

doi:10.1016/j.pmrj.2018.02.011

The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke: A Secondary Analysis From a Double-Blind, Randomized Trial

Hyun Mi Oh, Geun Young Park, Young Min Choi, Hyung Jung Koo, Yongjun Jang, Sun Im

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: There are no guidelines on the ideal time to inject botulinum toxin type A (BT-A) for lower leg spasticity in stroke patients. An early injection may produce unwanted weakness, interfering with gait recovery. Objective: To evaluate whether the outcomes after BT-A injection for plantarflexion spasticity can be different according to stroke chronicity. Design: A secondary analysis study from a double-blinded, randomized trial with group reclassification according to stroke chronicity. Setting: Two rehabilitation centers. Participants: Stroke participants (n = 40) with plantar flexor spasticity, treated with BT-A (200 units) into the gastrocnemius muscle. Methods: Outcome parameters were reanalyzed serially using 2-way repeated measures of analysis of variance (ANOVA), at baseline and 2, 4, and 8 weeks postinjection. Subjects were reclassified into 3 groups: early, within 6 months (n = 12); middle, between 6 months and 1 year (n = 14); and late, between 1 and 2 years from stroke onset (n = 12). Main Outcome Measures: The Modified Ashworth Scale, clonus scale, 10-m walking test, ABILOCO, and the Functional Ambulation Category. Results: The 2-way repeated measures of ANOVA showed improvement in gait and spasticity after injection in the 3 groups. Significant improvement in the Modified Ashworth Scale (P <.001) was observed, starting from the post–2 week injection period. Improvement of gait as assessed by the functional measurement ABILOCO and the Functional Ambulation Category (P <.001) were observed in all 3 groups, mostly at the post–8 week injection period. Conclusions: Our serial measurements of the outcome parameters indicated that BT-A could be expected to lead to consistent improvement in both the muscle tone and gait quality in those with plantar flexor spasticity regardless of stroke chronicity, including those injected as early as within the first 6 months.

Original language	English
Pages (from-to)	789-797
Number of pages	9
Journal	PM and R
Volume	10
Issue number	8
DOIs	https://doi.org/10.1016/j.pmrj.2018.02.011
State	Published - Aug 2018

Bibliographical note

Funding Information:
The study was supported by an unrestricted grant from Allergan and by the Institute of Clinical Medicine Research of Bucheon St. Mary’s Hospital, Research Fund (BCMC10AH07). The statistical analysis was supported by the Catholic Research Coordinating Center of the Korean Health 21 R&D Project (A070001).

Publisher Copyright:
© 2018 American Academy of Physical Medicine and Rehabilitation

Access to Document

10.1016/j.pmrj.2018.02.011

Cite this

@article{58e604f2bc4940a6a10bda64e0164957,

title = "The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke: A Secondary Analysis From a Double-Blind, Randomized Trial",

abstract = "Background: There are no guidelines on the ideal time to inject botulinum toxin type A (BT-A) for lower leg spasticity in stroke patients. An early injection may produce unwanted weakness, interfering with gait recovery. Objective: To evaluate whether the outcomes after BT-A injection for plantarflexion spasticity can be different according to stroke chronicity. Design: A secondary analysis study from a double-blinded, randomized trial with group reclassification according to stroke chronicity. Setting: Two rehabilitation centers. Participants: Stroke participants (n = 40) with plantar flexor spasticity, treated with BT-A (200 units) into the gastrocnemius muscle. Methods: Outcome parameters were reanalyzed serially using 2-way repeated measures of analysis of variance (ANOVA), at baseline and 2, 4, and 8 weeks postinjection. Subjects were reclassified into 3 groups: early, within 6 months (n = 12); middle, between 6 months and 1 year (n = 14); and late, between 1 and 2 years from stroke onset (n = 12). Main Outcome Measures: The Modified Ashworth Scale, clonus scale, 10-m walking test, ABILOCO, and the Functional Ambulation Category. Results: The 2-way repeated measures of ANOVA showed improvement in gait and spasticity after injection in the 3 groups. Significant improvement in the Modified Ashworth Scale (P <.001) was observed, starting from the post–2 week injection period. Improvement of gait as assessed by the functional measurement ABILOCO and the Functional Ambulation Category (P <.001) were observed in all 3 groups, mostly at the post–8 week injection period. Conclusions: Our serial measurements of the outcome parameters indicated that BT-A could be expected to lead to consistent improvement in both the muscle tone and gait quality in those with plantar flexor spasticity regardless of stroke chronicity, including those injected as early as within the first 6 months.",

author = "Oh, {Hyun Mi} and Park, {Geun Young} and Choi, {Young Min} and Koo, {Hyung Jung} and Yongjun Jang and Sun Im",

note = "Funding Information: The study was supported by an unrestricted grant from Allergan and by the Institute of Clinical Medicine Research of Bucheon St. Mary{\textquoteright}s Hospital, Research Fund (BCMC10AH07). The statistical analysis was supported by the Catholic Research Coordinating Center of the Korean Health 21 R&D Project (A070001). Publisher Copyright: {\textcopyright} 2018 American Academy of Physical Medicine and Rehabilitation",

year = "2018",

month = aug,

doi = "10.1016/j.pmrj.2018.02.011",

language = "English",

volume = "10",

pages = "789--797",

journal = "PM and R",

issn = "1934-1482",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke

T2 - A Secondary Analysis From a Double-Blind, Randomized Trial

AU - Oh, Hyun Mi

AU - Park, Geun Young

AU - Choi, Young Min

AU - Koo, Hyung Jung

AU - Jang, Yongjun

AU - Im, Sun

N1 - Funding Information: The study was supported by an unrestricted grant from Allergan and by the Institute of Clinical Medicine Research of Bucheon St. Mary’s Hospital, Research Fund (BCMC10AH07). The statistical analysis was supported by the Catholic Research Coordinating Center of the Korean Health 21 R&D Project (A070001). Publisher Copyright: © 2018 American Academy of Physical Medicine and Rehabilitation

PY - 2018/8

Y1 - 2018/8

N2 - Background: There are no guidelines on the ideal time to inject botulinum toxin type A (BT-A) for lower leg spasticity in stroke patients. An early injection may produce unwanted weakness, interfering with gait recovery. Objective: To evaluate whether the outcomes after BT-A injection for plantarflexion spasticity can be different according to stroke chronicity. Design: A secondary analysis study from a double-blinded, randomized trial with group reclassification according to stroke chronicity. Setting: Two rehabilitation centers. Participants: Stroke participants (n = 40) with plantar flexor spasticity, treated with BT-A (200 units) into the gastrocnemius muscle. Methods: Outcome parameters were reanalyzed serially using 2-way repeated measures of analysis of variance (ANOVA), at baseline and 2, 4, and 8 weeks postinjection. Subjects were reclassified into 3 groups: early, within 6 months (n = 12); middle, between 6 months and 1 year (n = 14); and late, between 1 and 2 years from stroke onset (n = 12). Main Outcome Measures: The Modified Ashworth Scale, clonus scale, 10-m walking test, ABILOCO, and the Functional Ambulation Category. Results: The 2-way repeated measures of ANOVA showed improvement in gait and spasticity after injection in the 3 groups. Significant improvement in the Modified Ashworth Scale (P <.001) was observed, starting from the post–2 week injection period. Improvement of gait as assessed by the functional measurement ABILOCO and the Functional Ambulation Category (P <.001) were observed in all 3 groups, mostly at the post–8 week injection period. Conclusions: Our serial measurements of the outcome parameters indicated that BT-A could be expected to lead to consistent improvement in both the muscle tone and gait quality in those with plantar flexor spasticity regardless of stroke chronicity, including those injected as early as within the first 6 months.

AB - Background: There are no guidelines on the ideal time to inject botulinum toxin type A (BT-A) for lower leg spasticity in stroke patients. An early injection may produce unwanted weakness, interfering with gait recovery. Objective: To evaluate whether the outcomes after BT-A injection for plantarflexion spasticity can be different according to stroke chronicity. Design: A secondary analysis study from a double-blinded, randomized trial with group reclassification according to stroke chronicity. Setting: Two rehabilitation centers. Participants: Stroke participants (n = 40) with plantar flexor spasticity, treated with BT-A (200 units) into the gastrocnemius muscle. Methods: Outcome parameters were reanalyzed serially using 2-way repeated measures of analysis of variance (ANOVA), at baseline and 2, 4, and 8 weeks postinjection. Subjects were reclassified into 3 groups: early, within 6 months (n = 12); middle, between 6 months and 1 year (n = 14); and late, between 1 and 2 years from stroke onset (n = 12). Main Outcome Measures: The Modified Ashworth Scale, clonus scale, 10-m walking test, ABILOCO, and the Functional Ambulation Category. Results: The 2-way repeated measures of ANOVA showed improvement in gait and spasticity after injection in the 3 groups. Significant improvement in the Modified Ashworth Scale (P <.001) was observed, starting from the post–2 week injection period. Improvement of gait as assessed by the functional measurement ABILOCO and the Functional Ambulation Category (P <.001) were observed in all 3 groups, mostly at the post–8 week injection period. Conclusions: Our serial measurements of the outcome parameters indicated that BT-A could be expected to lead to consistent improvement in both the muscle tone and gait quality in those with plantar flexor spasticity regardless of stroke chronicity, including those injected as early as within the first 6 months.

UR - http://www.scopus.com/inward/record.url?scp=85050356993&partnerID=8YFLogxK

U2 - 10.1016/j.pmrj.2018.02.011

DO - 10.1016/j.pmrj.2018.02.011

M3 - Article

C2 - 29510234

AN - SCOPUS:85050356993

SN - 1934-1482

VL - 10

SP - 789

EP - 797

JO - PM and R

JF - PM and R

IS - 8

ER -

The Effects of Botulinum Toxin Injections on Plantar Flexor Spasticity in Different Phases After Stroke: A Secondary Analysis From a Double-Blind, Randomized Trial

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this